Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALPG | P10696 | 2/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | IDH1 | O75874 | 2/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512289 | 1.00 | TDP1 (0.48) | TDP1L3MBTL1BRD4KDM4ELMNA | |
| SCHEMBL2509350 | 0.89 | JAK2 (0.52) | TDP1L3MBTL1BRD4KDM4ELMNA | |
| SCHEMBL2509348 | 0.89 | JAK2 (0.52) | TDP1L3MBTL1BRD4KDM4ELMNA | |
| SCHEMBL2511378 | 0.86 | BRD4 (0.50) | TDP1L3MBTL1BRD4KDM4ELMNA | |
| SCHEMBL2511375 | 0.86 | BRD4 (0.50) | TDP1L3MBTL1BRD4KDM4ELMNA | |
| SCHEMBL2506187 | 0.75 | BRD4 (0.51) | TDP1L3MBTL1BRD4KDM4ELMNA | |
| SCHEMBL2506182 | 0.75 | BRD4 (0.51) | TDP1L3MBTL1BRD4KDM4ELMNA | |
| SCHEMBL2509183 | 0.74 | BRD4 (0.50) | TDP1L3MBTL1BRD4KDM4ELMNA | |
| SCHEMBL2509182 | 0.74 | BRD4 (0.50) | TDP1L3MBTL1BRD4KDM4ELMNA | |
| SCHEMBL8050377 | 0.72 | CYP11B1 (0.65) | TDP1L3MBTL1BRD4KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013019655-A2 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2013-02-07 | — | — | WO | claimed |
| US-20110301159-A1 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-12-08 | — | — | US | claimed |
| EP-2376425-A2 | KINASE INHIBITOR COMPOUNDS | University of Florida Research Foundation, Inc. (US) | 2011-10-19 | — | — | EP | claimed |
| WO-2010068710-A2 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-20140248634-A1 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2013019655-A2 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20110301159-A1 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2376425-A2 | KINASE INHIBITOR COMPOUNDS | University of Florida Research Foundation, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010068710-A2 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301159-A1 | KINASE INHIBITOR COMPOUNDS | JAK2, JAK1, JAK3 | TDP1 1030/4885L3MBTL1 970/4885BRD4 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.